Document:

EX-10.73

 Exhibit 10.73 

SHARE REPURCHASE AGREEMENT 

dated as of 

March 18, 2019 

between 
 AXA S.A.

 and 
 AXA
Equitable Holdings, Inc. 

 Table of Contents 

Page 
 Article
 1 
 Sale and Repurchase 
  

					
	 1.1
	 	 Repurchase
	  	1
	 1.2
	 	 Closing
	  	1
	 1.3
	 	 Closing Conditions
	  	2

 Article 2 

Representations and Warranties of AXA 
  

					
	 2.1
	 	 Existence; Power and Authority
	  	3
	 2.2
	 	 Authorization
	  	3
	 2.3
	 	 No Conflicts
	  	3
	 2.4
	 	 Title
	  	3

 Article 3 

Representations and Warranties of the Company 
  

					
	 3.1
	 	 Existence; Power and Authority
	  	3
	 3.2
	 	 Authorization
	  	3
	 3.3
	 	 No Conflicts
	  	3
	 3.4
	 	 Sufficient Funds
	  	4

 Article 4 

Miscellaneous 
  

					
	 4.1
	 	 Termination
	  	4
	 4.2
	 	 Further Assurances
	  	4
	 4.3
	 	 Expenses
	  	4
	 4.4
	 	 Survival
	  	4
	 4.5
	 	 Amendments and Waivers
	  	4
	 4.6
	 	 Assignment; Binding Agreement
	  	4
	 4.7
	 	 No Third Party Beneficiaries
	  	4
	 4.8
	 	 Entire Agreement
	  	4
	 4.9
	 	 Severability
	  	5
	 4.10
	 	 Counterparts
	  	5
	 4.11
	 	 GOVERNING LAW
	  	5
	 4.12
	 	 CONSENT TO JURISDICTION AND SERVICE OF PROCESS; WAIVER OF JURY TRIAL

	  	5
	 4.13
	 	 Notices
	  	5
	 4.14
	 	 Interpretation
	  	6

  

  
 ii 

 SHARE REPURCHASE AGREEMENT 

This Share Repurchase Agreement, dated as of March 18, 2019 (this “Agreement”), is made between AXA S.A., a
société anonyme organized under the laws of France (“AXA”), and AXA Equitable Holdings, Inc., a Delaware corporation (the “Company”). 

WHEREAS, on February 14, 2019, the Company received notice from AXA pursuant to Section 2.2(a) of the Registration Rights
Agreement, dated May 4, 2018, between the Company and AXA; 
 WHEREAS, the Company has filed on or about the date hereof a
registration statement on Form S-1 registering shares of common stock of the Company, par value $0.01 (the “Common Stock”), owned by AXA for sale in an underwritten registered offering (the
“Secondary Offering”); 
 WHEREAS, concurrently with the Secondary Offering, AXA wishes to sell to the Company, and
the Company wishes to purchase from AXA, shares of Common Stock on the terms and subject to the conditions set forth in this Agreement (the “Repurchase Transaction”); and 

WHEREAS, the independent and disinterested directors of the audit committee (the “Committee”) of the board of
directors of the Company (the “Board”) have approved the Repurchase Transaction. 
 NOW, THEREFORE, in consideration
of the mutual promises and covenants set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree as follows: 

Article 1 

SALE AND REPURCHASE 
 
1.1    Repurchase. On the terms and subject to the conditions set forth in this Agreement, at the Closing (as defined below), AXA shall sell and transfer to the Company, and the Company shall purchase from AXA,
30,000,000 shares of Common Stock (the “Repurchased Shares”), provided that the number of Repurchased Shares multiplied by the Per Share Purchase Price may not exceed $800 million. The price for each Repurchased Share
shall be the per share price to be paid by the underwriters to AXA in connection with the Secondary Offering, pursuant to that certain underwriting agreement to be entered into by and among AXA, the Company and each of the underwriters party thereto
(which price AXA hereby represents to the Company is net of all underwriting discounts and commissions payable by AXA to the underwriters in connection with the Secondary Offering) (the “Per Share Purchase Price”). 

1.2    Closing. The closing of the Repurchase Transaction (the
“Closing”) shall be held at the offices of Debevoise & Plimpton LLP, 919 Third Avenue, New York, New York 10022 at the time specified for the closing in the underwriting agreement for the Secondary Offering, subject to the

 
satisfaction or waiver of the conditions set forth in Section 1.3 below (the date on which the Closing actually occurs is referred to herein as the “Closing Date”). At the
Closing: 
 (a)    AXA shall deliver or cause to be delivered to the Company all right, title and interest in and to the
Repurchased Shares, free and clear of all liens, claims, security interests and other encumbrances, together with all documentation reasonably necessary to transfer to the Company such right, title and interest. 

(b)    The Company shall pay to AXA the aggregate Per Share Purchase Price for the Repurchased Shares in immediately
available funds by wire transfer to an account in accordance with the instructions provided by AXA to the Company no later than two business days prior to the Closing. 

(c)    AXA agrees to pay all stamp, stock transfer and similar duties, if any, in connection with the Repurchase
Transaction. 
 1.3    Closing Conditions. 

(a)    The obligation of AXA to sell the Repurchased Shares to the Company and the obligation of the Company to purchase
and pay for the Repurchased Shares on the Closing Date are subject to the consummation of the Secondary Offering. 

(b)    The obligation of the Company to purchase and pay for the Repurchased Shares on the Closing Date is subject to the
satisfaction or waiver of the following additional conditions: 
 (i)    each representation and warranty made by AXA in
Article 2 below shall be true and correct on and as of the Closing Date as though made as of the Closing Date. 

(ii)    that after giving effect to the Repurchase Transaction (A) the actual, current value of the assets of
the Company will exceed the total amount of the Company’s total liabilities by an amount greater than the Company’s capital as defined in the Delaware General Corporation Law; (B) the Company will be able to pay its liabilities
as they become absolute and mature; (C) the Company will not have an unreasonably small amount of capital for the business in which it is engaged or intends to engage; and (D) the Company will be able to continue as a going
concern. 
 (iii)    the Committee shall have received an opinion from a nationally recognized investment banking or
financial advisory firm regarding the Per Share Purchase Price to be paid by the Company (which opinion has not been withdrawn prior to the Closing), in a form acceptable to the Committee. 

(iv)    that, immediately after giving effect to the Secondary Offering and the Repurchase Transaction, AXA owns less than
50% of the outstanding Common Stock. 
 (c)    The obligation of AXA to sell the Repurchased Shares on the Closing Date
is subject to the additional condition that each representation and warranty made by the Company in Article 3 below shall be true and correct on and as of the Closing Date as though made as of the Closing Date. 

  
 2 

 Article 2 

REPRESENTATIONS AND WARRANTIES OF AXA 

AXA hereby makes the following representations and warranties to the Company: 

2.1    Existence; Power and Authority. AXA has been duly incorporated and is
validly exiting as a société aonyme under French law, with full power and authority to execute and perform its obligations under this Agreement; and all action required to be taken for due and proper
authorization, execution and delivery by it of this Agreement and the consummation of the transaction contemplated hereby has been duly and validly taken. 

2.2    Authorization. This Agreement has been duly authorized, executed and
delivered by or on behalf of AXA. The place of execution of this Agreement by or on behalf of AXA was New York, New York. 
 
2.3    No Conflicts. The execution and delivery by AXA of, and the performance by AXA of its obligations under, this Agreement and the consummation by AXA of any other of the transactions contemplated hereby, or the
fulfillment by AXA of such terms will not result in a breach of any of the terms or provisions of, or constitute a default under, any instrument, agreement or order to which AXA is a party or by which AXA is bound or infringe any law, regulation,
order, rule, decree or statute applicable to AXA and are not contrary to the provisions of the constitutional documents of AXA. 
 
2.4    Title. AXA has, and on the Closing Date will have, valid title to, or a valid “security entitlement” within the meaning of Section 8-501 of the New York
Uniform Commercial Code in respect of, the Repurchased Shares free and clear of all security interests, claims, liens, equities or other encumbrances and the legal right and power, and all authorization and approval required by law, to enter into
this Agreement and to sell, transfer and deliver the Repurchased Shares or a security entitlement in respect of such Repurchased Shares. 

Article 3 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby makes the following representations and warranties to AXA: 

3.1    Existence; Power and Authority. The Company has been duly incorporated, is
validly existing as a corporation in good standing under the laws of the State of Delaware, has the corporate power and authority to execute and perform its obligations under this Agreement; and all action required to be taken for due and proper
authorization, execution and delivery by it of this Agreement and the consummation of the transaction contemplated hereby has been duly and validly taken. 

3.2    Authorization. This Agreement has been duly authorized, executed and
delivered by or on behalf of the Company. 
 3.3    No Conflicts. The execution
and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement and the consummation by the Company of any other of the transactions contemplated hereby, or the fulfillment by the

  
 3 

 
Company of such terms will not result in a breach of any of the terms or provisions of, or constitute a default under, any instrument, agreement or order to which the Company is a party or
by which the Company is bound or infringe any law, regulation, order, rule, decree or statute applicable to the Company and are not contrary to the provisions of the constitutional documents of the Company. 

3.4    Sufficient Funds. The Company will have, as of the Closing Date, access to
legally available funds sufficient to consummate the Repurchase Transaction. 
 Article 4 

MISCELLANEOUS 
 
4.1    Termination. This Agreement may be terminated prior to the Closing (a) by mutual written consent of the Company (at the direction of the disinterested and independent directors of the Committee) and
AXA or (b) by either the Company (at the direction of the disinterested and independent directors of the Committee) or AXA on or after 6:00 p.m. Eastern Time on April 12, 2019 if the Closing shall not have occurred by such date.

 4.2    Further Assurances. Each party hereto agrees to execute and deliver,
or cause to be executed and delivered, such agreements, instruments and other documents, and take such other actions consistent with the terms of this Agreement, as the other party may reasonably require from time to time in order to carry out the
purposes of this Agreement. 
 4.3    Expenses. Each party agrees to pay its
own costs and expenses associated with this Agreement and the Repurchase Transaction. 

4.4    Survival. All representations and warranties contained herein or made in
writing by any party in connection herewith shall survive the execution and delivery of this Agreement and the consummation of the transactions contemplated thereby. 

4.5    Amendments and Waivers. Except as otherwise provided herein, the
provisions of this Agreement may be amended or waived only by written agreement executed by the parties hereto. 
 
4.6    Assignment; Binding Agreement. This Agreement and the rights and obligations arising hereunder shall inure to the benefit of and be binding upon the parties hereto, and neither party may assign any of its rights
or delegate any of its obligations hereunder without the express written consent of the other party. 

4.7    No Third Party Beneficiaries. Nothing in this Agreement shall convey any
rights upon any person or entity which is not a party or a successor or permitted assignee of a party to this Agreement. 
 
4.8    Entire Agreement. This Agreement constitutes the sole and entire agreement among the parties with respect to the subject matter of this Agreement, and supersedes all prior representations, agreements and
understandings, written or oral, with respect to the subject matter hereof. 

  
 4 

 4.9    Severability. In the
event that any one or more of the provisions contained herein, or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision
in every other respect and of the remaining provisions contained herein shall not be in any way impaired thereby, it being intended that all of the rights and privileges of the parties shall be enforceable to the fullest extent permitted by law. To
the extent that any such provision is so held to be invalid, illegal or unenforceable, the parties shall in good faith use commercially reasonable efforts to find and effect an alternative means to achieve the same or substantially the same result
as that contemplated by such provision. 
 4.10    Counterparts. This Agreement
may be signed in any number of counterparts, each of which shall be deemed an original (including signatures delivered via facsimile or electronic mail) with the same effect as if the signatures thereto and hereto were upon the same instrument. The
parties hereto may deliver this Agreement by facsimile or by electronic mail and each party shall be permitted to rely on the signatures so transmitted to the same extent and effect as if they were original signatures. 

4.11    GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND INTERPRETED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF TO THE EXTENT THAT SUCH PRINCIPLES WOULD APPLY THE LAW OF
ANOTHER JURISDICTION. 
 4.12    CONSENT TO JURISDICTION AND SERVICE OF PROCESS;
WAIVER OF JURY TRIAL. Each party to this Agreement hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts located in the State of New York for any actions, suits or proceedings arising out of or relating to this
Agreement and the transactions contemplated thereby; provided that such consent to jurisdiction is solely for the purpose referred to in this Section 4.12 and shall not be deemed to be a general submission to the jurisdiction of said
courts or in the State of New York other than for such purpose. Each of the parties hereby agrees not to commence any such action, suit or proceeding other than before one of the above-named courts. EACH PARTY TO THIS AGREEMENT HEREBY WAIVES TO THE
FULLEST EXTENT PERMITTED BY LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

4.13    Notices. 

Unless otherwise provided in this Agreement, all notices and other communications provided for hereunder shall be dated and in writing and
shall be deemed to have been given (i) when delivered, if delivered personally, sent by confirmed telecopy or sent by registered or certified mail, return receipt requested, postage prepaid, provided that such delivery is completed
during normal business hours of the recipient, failing which such notice shall be deemed to have been given on the next business day, (ii) on the next business day if sent by overnight courier and delivered on such business day within
ordinary business hours and, if 

  
 5 

 
not, the next business day following delivery; and (iii) when received, if received during normal business hours and, if not, the next business day after receipt, if delivered by
means other than those specified above. Such notices shall be delivered to the address set forth below, or to such other address as a party shall have furnished to the other party in accordance with this Section. 

To AXA: 

25 Avenue Matignon 

75008 Paris, France 

Attention: General Counsel 

Telephone: +33 (1) 40 75 48 68 

E-mail: helen.browne@axa.com 

To the Company 

AXA Equitable Holdings, Inc. 

1290 Avenue of the Americas 

New York, New York 10104 

Attention: Dave S. Hattem, General Counsel 

Telephone: (212) 314-3863 

E-mail: dave.hattem@axa.us.com 

4.14    Interpretation. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 [Signature Page Follows]

  
 6 

 In witness whereof, the parties have caused this Share Repurchase Agreement to be executed
and delivered as of the date first above written. 
  

			
	 AXA S.A.

	 Executed in New York, New York

		
	 By:
	 	 /s/ Nicolas Leclercq

	 Name:
	 	 Nicolas Leclercq

	 Title:
	 	
Attorney-in-Fact

	
	 AXA EQUITABLE HOLDINGS, INC.

		
	 By:
	 	 /s/ Anders B. Malmström

	 Name:
	 	 Anders B. Malmström

	 Title:
	 	Senior Executive Vice President and Chief Financial Officer

 [Signature Page to Share Repurchase Agreement]Exhibit 10.9

 

	
 
    	

    

 

	
 
    	
October 22, 2018
    

 

Jackson Streeter

 

Dear Jackson:

 

Quanterix Corporation (the “Company”) is pleased to offer you the full-time position of SVP, Corporate Development and Strategy, reporting to me, pending Board approval.  Your effective date of hire will be November 12, 2018.  We are excited about the prospect of you joining our team.

 

Salary:  The Company will pay you a salary at an annual rate of $300,000, paid at a bi-weekly rate of $11,538.46 (subject to periodic review and adjustment at the discretion of the Company).

 

Bonus:  You will be eligible to receive an annual performance bonus.  The Company will target the bonus at up to 50% of your annual base salary earnings.  The actual bonus percentage is discretionary and will be subject to your achievement of the metrics and goals established by and agreed to with Kevin Hrusovsky.  The bonus also will be subject to your employment for the full period covered by the bonus, approval by and adjustment at the discretion of the Company and Company’s Board of Directors, and the terms of any applicable bonus plan. You must be actively employed by Quanterix on the date the bonus is paid to receive a performance bonus.

 

Benefits:  You will be eligible to participate in the employee benefits and insurance programs generally made available to its full-time employees, including medical insurance, dental insurance, 401K Plan and match, ESPP, Flexible Spending Account, term life insurance, and short and long term disability insurance.  Details of these benefits programs, including mandatory employee contributions, will be made available to you when you start.  You

 

 

 

also will be eligible to receive paid vacation time.  You will be eligible for up to 20 days of paid vacation per year, which shall accrue on a prorated basis.  Other provisions of the Company’s vacation policy are set forth in the policy itself.

 

Stock Options & RSUs:  You will be eligible to participate in the Company’s stock option program, subject to approval by the Compensation Committee.  We will recommend to the Compensation Committee to approve that you be granted 28,441 Restricted Stock Units (RSUs) and an option to purchase 66,143 shares of the Company’s common stock at the stock’s then fair market value. The RSUs and options will vest over four years, with 25% vesting on the first anniversary of your start date, and the remaining vesting ratably on a monthly basis over the next three years. Your eligibility for stock options will be governed by the Quanterix 2017 Employee, Director and Consultant Equity Incentive Plan and any associated stock option agreement required to be entered into by you and the Company.

 

Representation Regarding Other Obligations:  This offer is conditioned on your representation that you are not subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company.  If you have entered into any agreement that may restrict your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible.

 

Other Terms:  Your employment with the Company shall be on an at-will basis.  In other words, you or the Company may terminate employment for any reason and at any time, with or without notice.  Similarly, the terms of employment outlined in this letter are subject to change at any time.  You also will be required to sign the Company’s standard “Employee Non-Solicitation, Confidentiality and Assignment Agreement” as a condition of your employment.  A copy of that Agreement is enclosed.  In addition, as with all employees, our offer to you is contingent on your submission of satisfactory proof of your identity and your legal authorization to work in the United States.

 

We are excited about the opportunity to work with you at Quanterix.  If you have any questions about this information, please do not hesitate to call.  Otherwise, please confirm your acceptance of this offer of employment by signing below and returning a copy to me no later than October 23, 2018.

 

 

We are confident that with your background and skills, you will have an immediate positive impact on our organization.

 

 

Sincerely,

 

	
/s/ Kevin Hrusovsky
    	
 
    
	
 
    	
 
    
	
Kevin Hrusovsky
    	
 
    
	
CEO and Executive   Chairman
    	
 
    

 

 

Offer accepted:

 

	
/s/ Jackson Streeter
    	
 
    	
10/25/18
    
	
Jackson Streeter
    	
 
    	
Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]